1. Home
  2. RIGL vs NEN Comparison

RIGL vs NEN Comparison

Compare RIGL & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • NEN
  • Stock Information
  • Founded
  • RIGL 1996
  • NEN 1977
  • Country
  • RIGL United States
  • NEN United States
  • Employees
  • RIGL N/A
  • NEN N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • NEN Building operators
  • Sector
  • RIGL Health Care
  • NEN Real Estate
  • Exchange
  • RIGL Nasdaq
  • NEN Nasdaq
  • Market Cap
  • RIGL 334.5M
  • NEN 277.7M
  • IPO Year
  • RIGL 2000
  • NEN N/A
  • Fundamental
  • Price
  • RIGL $18.28
  • NEN $79.85
  • Analyst Decision
  • RIGL Buy
  • NEN
  • Analyst Count
  • RIGL 5
  • NEN 0
  • Target Price
  • RIGL $36.40
  • NEN N/A
  • AVG Volume (30 Days)
  • RIGL 205.1K
  • NEN 503.0
  • Earning Date
  • RIGL 05-06-2025
  • NEN 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • NEN 6.20%
  • EPS Growth
  • RIGL N/A
  • NEN 58.97
  • EPS
  • RIGL 2.08
  • NEN 4.56
  • Revenue
  • RIGL $203,077,000.00
  • NEN $82,610,147.00
  • Revenue This Year
  • RIGL $24.45
  • NEN N/A
  • Revenue Next Year
  • RIGL $7.23
  • NEN N/A
  • P/E Ratio
  • RIGL $8.77
  • NEN $17.50
  • Revenue Growth
  • RIGL 70.16
  • NEN 6.83
  • 52 Week Low
  • RIGL $7.48
  • NEN $67.50
  • 52 Week High
  • RIGL $29.82
  • NEN $84.00
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 47.44
  • NEN 58.30
  • Support Level
  • RIGL $17.65
  • NEN $76.00
  • Resistance Level
  • RIGL $19.75
  • NEN $78.75
  • Average True Range (ATR)
  • RIGL 1.46
  • NEN 0.31
  • MACD
  • RIGL -0.02
  • NEN 0.26
  • Stochastic Oscillator
  • RIGL 16.39
  • NEN 96.01

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

Share on Social Networks: